Inflarx N.V. (IFRX)
NASDAQ:IFRX
Want to see IFRX full AI Analyst Report?
IFRX Stock Chart & Stats
$1.59
-$0.16(-6.27%)
At close: 4:00 PM EST
$1.59
-$0.16(-6.27%)
Day’s Range― - ―
52-Week Range$0.74 - $2.95
Previous CloseN/A
Volume66.97K
Average Volume (3M)2.83M
Market Cap
$353.50M
Enterprise Value$134.48M
Total Cash (Recent Filing)$39.84M
Total Debt (Recent Filing)$823.88K
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Aug 06, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding147,292,860
10 Day Avg. Volume1,106,990
30 Day Avg. Volume2,833,233
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.39
Price to Sales (P/S)1972.04
P/FCF Ratio-1.70
Enterprise Value/Market Cap0.38
Enterprise Value/Revenue4.58K
Enterprise Value/Gross Profit-18.60
Enterprise Value/Ebitda-3.17
Forecast
1Y Price Target
$8.00Price Target Upside403.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$13.29K
Bulls Say, Bears Say
Bulls Say
Extended Funding RunwayManagement shifted focus to izicopan and reports cash + strategic actions that are expected to fund planned izicopan programs, key PoC and Phase 2 readouts, and operations through 2029. This materially reduces near-term financing pressure and supports multi-year program execution.
Favorable Izicopan Safety ProfilePreclinical data showing markedly lower reactive metabolite formation versus the comparator, plus prior tolerability and PD signals, suggest a differentiated safety and DDI profile. This improves chances for chronic use, regulatory acceptance, and partner interest across complement-mediated renal and inflammatory indications.
Governance And Financing FlexibilityShareholder-approved capital and governance changes, plus reappointment of leadership, provide the board legal flexibility to raise capital, structure partnerships, and retain executives. That capability supports strategic financing and alignment while the company advances mid-stage programs.
Bears Say
Sustained Cash BurnOperating and free cash flow remain materially negative and closely track net losses, indicating real cash consumption rather than non‑cash accounting charges. Over time this necessitates frequent capital raises or partnerships, creating execution risk if clinical milestones slip or financing windows tighten.
No Commercial Revenue; Persistent LossesThe company remains clinical-stage with negligible recurring revenue and multi-year net losses. Lack of product revenues means progress depends entirely on clinical success and external funding; continued losses weaken ability to self-fund later-stage trials or commercial launches without dilution or partners.
Eroding Equity And Dilution RiskMaterial declines in equity and total assets reflect cumulative cash burn and prior financings. Combined with recent large share issuances, this raises dilution risk for existing shareholders and signals that value per share is sensitive to future financing outcomes and successful clinical readouts.
InflaRx News
IFRX FAQ
What was Inflarx N.V.’s price range in the past 12 months?
Inflarx N.V. lowest stock price was $0.74 and its highest was $2.95 in the past 12 months.
What is Inflarx N.V.’s market cap?
Inflarx N.V.’s market cap is $353.50M.
When is Inflarx N.V.’s upcoming earnings report date?
Inflarx N.V.’s upcoming earnings report date is Aug 06, 2026 which is in 66 days.
How were Inflarx N.V.’s earnings last quarter?
Inflarx N.V. released its earnings results on May 07, 2026. The company reported -$0.093 earnings per share for the quarter, beating the consensus estimate of -$0.137 by $0.044.
Is Inflarx N.V. overvalued?
According to Wall Street analysts Inflarx N.V.’s price is currently Undervalued.
Does Inflarx N.V. pay dividends?
Inflarx N.V. does not currently pay dividends.
What is Inflarx N.V.’s EPS estimate?
Inflarx N.V.’s EPS estimate is -0.07.
How many shares outstanding does Inflarx N.V. have?
Inflarx N.V. has 147,292,860 shares outstanding.
What happened to Inflarx N.V.’s price movement after its last earnings report?
Inflarx N.V. reported an EPS of -$0.093 in its last earnings report, beating expectations of -$0.137. Following the earnings report the stock price went up 6%.
Which hedge fund is a major shareholder of Inflarx N.V.?
Currently, no hedge funds are holding shares in IFRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InflaRx Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (403.14% Upside)
$8.00 (403.14% Upside)
Blogger Sentiment
Bullish
IFRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
182.35%
12-Months-Change
Fundamentals
Return on Equity
-94.90%
Trailing 12-Months
Asset Growth
-40.06%
Trailing 12-Months
Company Description
Inflarx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
IFRX Stock 12 Month Forecast
Average Price Target
$8.00
▲(403.14% Upside)
Technical Analysis
Oramed Pharm
―
Atara Biotherapeutics
―
Anixa Biosciences
―
Clene
―
Acumen Pharmaceuticals
―
Ownership Overview
―
Insiders
0.03% Mutual Funds
9.30% Other Institutional Investors
90.67% Public Companies and
Individual Investors